IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (312)	1/23/1997 7:28:00 PM
From: Richard Belanger	of 1762

Thanks, Brad. The quantity of I-131 used in Coulter's Phase I (34 to 161 mCi) may or may not require hospitalization under the new rule. According to an NRC rep. that I talked to, there is a "guideline" value of 33 mCi for I-131, but the hospital might still be able to release the patient if they can demonstrate that no person other than the patient will receive a radiation dose exceeding the specified limit. I have some background in radiation dosimetry so I'll try to evaluate this further. By the way, the IDEC-Y2B8 treatment is not affected by the new rule, since it uses a yttrium-90 isotope that emits only beta particles which have a short range in tissue and will not expose persons other than the patient. Best regards, Rich

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next